Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status.

Blehaut H, Mircher C, Ravel A, Conte M, de Portzamparc V, Poret G, de Kermadec FH, Rethore MO, Sturtz FG.

PLoS One. 2010 Jan 11;5(1):e8394. doi: 10.1371/journal.pone.0008394.

2.

Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial.

Ellis JM, Tan HK, Gilbert RE, Muller DP, Henley W, Moy R, Pumphrey R, Ani C, Davies S, Edwards V, Green H, Salt A, Logan S.

BMJ. 2008 Mar 15;336(7644):594-7. doi: 10.1136/bmj.39465.544028.AE. Epub 2008 Feb 21.

3.

Hyperthyrotropinaemia in untreated subjects with Down's syndrome aged 6 months to 64 years: a comparative analysis.

Meyerovitch J, Antebi F, Greenberg-Dotan S, Bar-Tal O, Hochberg Z.

Arch Dis Child. 2012 Jul;97(7):595-8. doi: 10.1136/archdischild-2011-300806. Epub 2012 Apr 25.

PMID:
22535238
4.

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.

van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB.

Arthritis Rheum. 2001 Jul;44(7):1515-24.

5.

Effects of early thyroxine treatment on development and growth at age 10.7 years: follow-up of a randomized placebo-controlled trial in children with Down's syndrome.

Marchal JP, Maurice-Stam H, Ikelaar NA, Klouwer FC, Verhorstert KW, Witteveen ME, Houtzager BA, Grootenhuis MA, van Trotsenburg AS.

J Clin Endocrinol Metab. 2014 Dec;99(12):E2722-9. doi: 10.1210/jc.2014-2849.

PMID:
25243574
6.

Communicative gestures and vocabulary development in 36-month-old children with Down's syndrome.

Zampini L, D'Odorico L.

Int J Lang Commun Disord. 2009 Nov-Dec;44(6):1063-73. doi: 10.1080/13682820802398288.

PMID:
19105070
7.

Thyroid function in adults with Down's syndrome.

Murdoch JC, Ratcliffe WA, McLarty DG, Rodger JC, Ratcliffe JG.

J Clin Endocrinol Metab. 1977 Mar;44(3):453-8.

PMID:
138688
8.

Thyroid dysfunction in children with Down's syndrome.

Tüysüz B, Beker DB.

Acta Paediatr. 2001 Dec;90(12):1389-93.

PMID:
11853334
9.

Thyroid functions in children with Down's syndrome.

Unachak K, Tanpaiboon P, Pongprot Y, Sittivangkul R, Silvilairat S, Dejkhamron P, Sudasna J.

J Med Assoc Thai. 2008 Jan;91(1):56-61.

PMID:
18386545
10.

Studies of the thyroid function in children with Down's syndrome.

Schmidt BJ, Carvalho N, Ortega CC, Libermam J, Biazzi JM, Tapajós PM, Krynski S.

Arq Neuropsiquiatr. 1975 Mar;33(1):21-4.

PMID:
51614
11.

Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.

Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C; MEADOWS trial researchers.

Lancet. 2012 Feb 11;379(9815):528-36. doi: 10.1016/S0140-6736(11)61676-0. Epub 2012 Jan 10.

PMID:
22236802
12.

Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity.

Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Annerén G.

Arch Dis Child. 1998 Sep;79(3):242-5.

13.

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA, Tugwell P.

Cochrane Database Syst Rev. 2013 May 31;(5):CD000951. doi: 10.1002/14651858.CD000951.pub2. Review.

PMID:
23728635
14.

Development of Down's syndrome infants with and without heart defects and changes in their caretaking environment.

Barrera ME, Watson LJ, Adelstein A.

Child Care Health Dev. 1987 Mar-Apr;13(2):87-100.

PMID:
2953506
15.

Mirrow reactions of Down's syndrome infants and toddlers: cognitive underpinnings of self-recognition.

Mans L, Cicchetti D, Sroufe LA.

Child Dev. 1978 Dec;49(4):1247-50.

PMID:
153832
16.

Immune-endocrine status and coeliac disease in children with Down's syndrome: relationships with zinc and cognitive efficiency.

Licastro F, Mariani RA, Faldella G, Carpenè E, Guidicini G, Rangoni A, Grilli T, Bazzocchi G.

Brain Res Bull. 2001 May 15;55(2):313-7.

PMID:
11470333
17.

Follow-up of folinic acid supplementation for patients with cerebral folate deficiency and Kearns-Sayre syndrome.

Quijada-Fraile P, O'Callaghan M, Martín-Hernández E, Montero R, Garcia-Cazorla À, de Aragón AM, Muchart J, Málaga I, Pardo R, García-Gonzalez P, Jou C, Montoya J, Emperador S, Ruiz-Pesini E, Arenas J, Martin MA, Ormazabal A, Pineda M, García-Silva MT, Artuch R.

Orphanet J Rare Dis. 2014 Dec 24;9:217. doi: 10.1186/s13023-014-0217-2.

18.

Lexical and syntactic development in Italian children with Down's syndrome.

Zampini L, D'Odorico L.

Int J Lang Commun Disord. 2011 Jul-Aug;46(4):386-96. doi: 10.3109/13682822.2010.508764. Epub 2011 May 27.

PMID:
21771215
19.

Understanding mental retardation in Down's syndrome using trisomy 16 mouse models.

Galdzicki Z, Siarey RJ.

Genes Brain Behav. 2003 Jun;2(3):167-78. Review.

20.

[The diagnostics and developmental stimulation of small children with 21 trisomy in compliance with thyroid function].

Mysłek-Prucnal M, Sadowska L, Gruna-Ozarowska A.

Pediatr Endocrinol Diabetes Metab. 2008;14(4):243-7. Polish.

PMID:
19239793

Supplemental Content

Support Center